MX2024005389A - Metodos de tratamiento de la depresion respiratoria modulada por un agente no opioide. - Google Patents
Metodos de tratamiento de la depresion respiratoria modulada por un agente no opioide.Info
- Publication number
- MX2024005389A MX2024005389A MX2024005389A MX2024005389A MX2024005389A MX 2024005389 A MX2024005389 A MX 2024005389A MX 2024005389 A MX2024005389 A MX 2024005389A MX 2024005389 A MX2024005389 A MX 2024005389A MX 2024005389 A MX2024005389 A MX 2024005389A
- Authority
- MX
- Mexico
- Prior art keywords
- modulated
- treatment
- methods
- opioid agent
- respiratory depression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163274722P | 2021-11-02 | 2021-11-02 | |
| PCT/US2022/048669 WO2023081185A1 (en) | 2021-11-02 | 2022-11-02 | Methods of treating respiratory depression modulated by a non-opioid agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005389A true MX2024005389A (es) | 2024-07-09 |
Family
ID=86147248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005389A MX2024005389A (es) | 2021-11-02 | 2022-11-02 | Metodos de tratamiento de la depresion respiratoria modulada por un agente no opioide. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12138267B2 (https=) |
| EP (1) | EP4426308A4 (https=) |
| JP (1) | JP2024540198A (https=) |
| KR (1) | KR20240101622A (https=) |
| CN (1) | CN118488840A (https=) |
| AU (1) | AU2022380482A1 (https=) |
| CA (1) | CA3236586A1 (https=) |
| MX (1) | MX2024005389A (https=) |
| TW (1) | TW202333730A (https=) |
| WO (1) | WO2023081185A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025511227A (ja) * | 2022-04-01 | 2025-04-15 | エナラーレ セラピューティクス インコーポレイテッド | 呼吸器刺激性経鼻製剤 |
| US20230414624A1 (en) * | 2022-06-24 | 2023-12-28 | Enalare Therapeutics Inc. | Methods of treating neurological ventilatory insufficiency |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4508715A (en) | 1981-07-01 | 1985-04-02 | University Of Georgia Research Foundation, Inc. | Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs |
| AU2011322147A1 (en) * | 2010-10-26 | 2013-04-18 | Alpharma Pharmaceuticals, Llc | Formulations and methods for attenuating respiratory depression induced by opioid overdose |
| US20120295911A1 (en) | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| AU2011336764B2 (en) * | 2010-11-29 | 2017-02-23 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| SG11201503505QA (en) | 2012-11-15 | 2015-06-29 | Galleon Pharmaceuticals Inc | Novel orally bioavailable breathing control modulating compounds, and methods of using same |
| WO2016007729A1 (en) | 2014-07-09 | 2016-01-14 | Lightlake Therapeutics Inc. | Co-packaged drug products |
| HK1245079A1 (zh) | 2015-06-30 | 2018-08-24 | 纽拉德有限公司 | 新颖呼吸控制调节化合物以及其制备和使用方法 |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| EP3833346A4 (en) | 2018-08-08 | 2022-08-03 | Torralva Medical Therapeutics LLC | Compositions for opiate and opioid prevention and reversal, and methods of their use |
-
2022
- 2022-11-02 CA CA3236586A patent/CA3236586A1/en active Pending
- 2022-11-02 AU AU2022380482A patent/AU2022380482A1/en active Pending
- 2022-11-02 MX MX2024005389A patent/MX2024005389A/es unknown
- 2022-11-02 EP EP22890702.8A patent/EP4426308A4/en active Pending
- 2022-11-02 CN CN202280080555.4A patent/CN118488840A/zh active Pending
- 2022-11-02 JP JP2024525777A patent/JP2024540198A/ja active Pending
- 2022-11-02 WO PCT/US2022/048669 patent/WO2023081185A1/en not_active Ceased
- 2022-11-02 US US17/979,192 patent/US12138267B2/en active Active
- 2022-11-02 KR KR1020247018353A patent/KR20240101622A/ko active Pending
- 2022-11-02 TW TW111141904A patent/TW202333730A/zh unknown
-
2024
- 2024-08-06 US US18/795,777 patent/US20250032496A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022380482A1 (en) | 2024-05-16 |
| JP2024540198A (ja) | 2024-10-31 |
| US20250032496A1 (en) | 2025-01-30 |
| EP4426308A1 (en) | 2024-09-11 |
| CA3236586A1 (en) | 2023-05-11 |
| US20230140606A1 (en) | 2023-05-04 |
| EP4426308A4 (en) | 2025-09-03 |
| US12138267B2 (en) | 2024-11-12 |
| WO2023081185A1 (en) | 2023-05-11 |
| TW202333730A (zh) | 2023-09-01 |
| CN118488840A (zh) | 2024-08-13 |
| KR20240101622A (ko) | 2024-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005389A (es) | Metodos de tratamiento de la depresion respiratoria modulada por un agente no opioide. | |
| ZA202500439B (en) | Therapeutic compounds for hiv virus infection | |
| ZA202207169B (en) | Methods, compositions, and vaccines for treating a virus infection | |
| MX2024003960A (es) | Compuestos antivirales que contienen nitrilo. | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| PH12022553222A1 (en) | Anthelmintic heterocyclic compounds | |
| MX2007005679A (es) | Metodo para tratamiento de desordenes de movimiento. | |
| UA107562C2 (uk) | Спосіб лікування псоріазу | |
| MX2022012812A (es) | Métodos para tratar el síndrome de liberación de citocinas. | |
| RU2008130963A (ru) | Лечение метастатического рака молочной железы | |
| FR2973229B1 (fr) | Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 4-(3-ethoxy-4-hydroxyphenyl)alkylcetone ou 2-ethoxy 4-hydroxyalkyl phenol | |
| MX2022009967A (es) | Compuestos para el tratamiento de la infeccion por coronavirus. | |
| ATE525084T1 (de) | Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus | |
| WO2022247920A9 (zh) | 喹啉胺类化合物、其制备方法及其在医药上的应用 | |
| BR112023000817A2 (pt) | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo | |
| ATE393625T1 (de) | Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen | |
| PH12022552110A1 (en) | Quinolyl phosphine oxide compound, and composition and application thereof | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| WO2020128614A8 (en) | Method for treating interstital lung disease | |
| RU2014123690A (ru) | Терапевтическое средство при артрозе | |
| PL423672A1 (pl) | Kompozycja farmaceutyczna zawierająca zebularynę oraz środek leczniczy do regeneracji ran | |
| MX2022014888A (es) | Propanodioles mononitrosilados y bisnitrosilados para su uso terapéutico. | |
| BR112023023702A2 (pt) | Métodos de tratamento da cistite intersticial/síndrome da dor na bexiga | |
| BR112022004659A2 (pt) | Métodos de tratamento com rifabutina, usos e composições | |
| BR112023016958A2 (pt) | Compostos para uso no tratamento de uma infecção por vírus envelopado |